Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 268 articles:
HTML format



Single Articles


    November 2023
  1. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    PubMed    



  2. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.
    J Hepatol. 2023 Nov 27:S0168-8278(23)05285-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  3. BALAGOPAL A, Thomas DL
    Genomics on the road to functional cure of hepatitis B.
    J Hepatol. 2023 Nov 18:S0168-8278(23)05276-5. doi: 10.1016/j.jhep.2023.
    PubMed    


  4. HUPPE D, Wedemeyer H, Cornberg M
    Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
    J Hepatol. 2023 Nov 3:S0168-8278(23)05234-0. doi: 10.1016/j.jhep.2023.
    PubMed    


    October 2023
  5. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
    Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
    J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  6. GUAN G, Zhang T, Ning J, Tao C, et al
    Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-alpha-treated patients with chronic hepatitis B.
    J Hepatol. 2023 Oct 17:S0168-8278(23)05175-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  7. PANDURANGI S, Malik A, Owens J, Valencia CA, et al
    Deleterious variants in TNFAIP3 are associated with type II and seronegative Pediatric autoimmune hepatitis.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05156-5. doi: 10.1016/j.jhep.2023.
    PubMed    


  8. GRONBAEK L, Gronbaek H
    Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
    PubMed    


  9. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  10. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    PubMed    


    September 2023
  11. CHUN HS, Papatheodoridis GV, Lee M, Lee HA, et al
    PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    J Hepatol. 2023 Sep 19:S0168-8278(23)05096-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  12. UZUN S, Zinner CP, Beenen AC, Alborelli I, et al
    Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
    J Hepatol. 2023;79:666-676.
    PubMed     Abstract available


  13. PERON JM, Larrue H, Izopet J, Buti M, et al
    The pressing need for a global HEV vaccine.
    J Hepatol. 2023;79:876-880.
    PubMed     Abstract available


    August 2023
  14. YU X, Long J, Xie Y, Zhang J, et al
    Immunomodulatory effects of tenofovir disoproxil fumarate and entecavir in treating hepatitis B virus infection.
    J Hepatol. 2023 Aug 18:S0168-8278(23)05061-4. doi: 10.1016/j.jhep.2023.
    PubMed    


  15. WAN YM, Wu HM, Huang SQ, Li HY, et al
    A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B." (J Hepatol. 2023 May;78(5):926-936.).
    J Hepatol. 2023 Aug 11:S0168-8278(23)05051-1. doi: 10.1016/j.jhep.2023.
    PubMed    


  16. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.
    PubMed    



  17. EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    PubMed     Abstract available


  18. DEVARBHAVI H, Asrani SK, Arab JP, Nartey YA, et al
    Global burden of liver disease: 2023 update.
    J Hepatol. 2023;79:516-537.
    PubMed     Abstract available


    July 2023
  19. GANE EJ, Kim W, Lim TH, Tangkijvanich P, et al
    First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
    J Hepatol. 2023 Jul 29:S0168-8278(23)05005-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  20. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.
    PubMed    


  21. TOSTI ME, Caminada S, Ferrigno L
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021: authors' reply to comments.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04999-1. doi: 10.1016/j.jhep.2023.
    PubMed    


  22. LENS S, Perez Del Pulgar S, Forns X
    The relevance of finding biomarkers to identify the best candidates for nucleos(t)ide analogue discontinuation in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04994-2. doi: 10.1016/j.jhep.2023.
    PubMed    


  23. LEMPP FA, Volz T, Cameroni E, Benigni F, et al
    Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
    J Hepatol. 2023 Jul 15:S0168-8278(23)04978-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  24. KLOTZ W, Herold M
    How to test antinuclear antibodies to diagnose autoimmune hepatitis.
    J Hepatol. 2023 Jul 13:S0168-8278(23)04983-8. doi: 10.1016/j.jhep.2023.
    PubMed    


  25. GUAN MC, Ding Q, Zhu H
    Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over one year ?
    J Hepatol. 2023 Jul 4:S0168-8278(23)04937-1. doi: 10.1016/j.jhep.2023.
    PubMed    


  26. OKAMOTO T, Okajima H, Ogawa E, Yurugi K, et al
    The protective association of HLA-B*52:01, HLA-C*12:02, and DQB1*06:01 alleles with severe acute hepatitis of unknown origin in Japanese children.
    J Hepatol. 2023 Jul 3:S0168-8278(23)04930-9. doi: 10.1016/j.jhep.2023.
    PubMed    


  27. DE MARTIN E, Laurent-Bellue A, Routier E, Samuel D, et al
    Acute cholestatic hepatitis in a patient with metastatic melanoma.
    J Hepatol. 2023;79:e13-e15.
    PubMed    


  28. JACHS M, Mandorfer M, Reiberger T
    Reply to: "3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta".
    J Hepatol. 2023;79:e49-e50.
    PubMed    


  29. JAGADISAN B, Verma A, Deheragoda M, Deep A, et al
    Outbreak of indeterminate acute liver failure in children with adenoviraemia - Not a new disease.
    J Hepatol. 2023;79:43-49.
    PubMed     Abstract available


    June 2023
  30. YANG F, Fan X, Yang L
    Dysregulation of the lysophosphatidylcholine/autotaxin/lysophosphatidic acid axis in autoimmune hepatitis is associated with monocyte activation.
    J Hepatol. 2023 Jun 29:S0168-8278(23)04934-6. doi: 10.1016/j.jhep.2023.
    PubMed    


  31. YANG H, Kim JH, Han JW, Lee SK, et al
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?'.
    J Hepatol. 2023 Jun 27:S0168-8278(23)00425-7. doi: 10.1016/j.jhep.2023.
    PubMed    


  32. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  33. GHANY MG, Buti M, Lampertico P, Lee HM, et al
    Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference.
    J Hepatol. 2023 Jun 21:S0168-8278(23)00417-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  34. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  35. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  36. GANE E, Lim YS, Kim JB, Jadhav V, et al
    Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  37. KHAN RS, Lalor PF, Thursz M, Newsome P, et al
    The role of neutrophils in alcohol-related hepatitis.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00346-X. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  38. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.
    PubMed    


  39. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    PubMed     Abstract available


    May 2023
  40. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.
    PubMed    


  41. ANDRADE RJ, Aithal GP, de Boer YS, Liberal R, et al
    Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
    J Hepatol. 2023 May 8:S0168-8278(23)00320-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available



  42. Clinical Practice Guidelines on Hepatitis Delta Virus.
    J Hepatol. 2023 May 5:S0168-8278(23)00317-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  43. VAN BOMMEL F, Stein K, Heyne R, Petersen J, et al
    A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2023;78:926-936.
    PubMed     Abstract available


    April 2023
  44. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.
    PubMed    


  45. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  46. HOLLNBERGER J, Liu Y, Xu S, Chang S, et al
    No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
    J Hepatol. 2023 Apr 27:S0168-8278(23)00313-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  47. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  48. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  49. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.
    PubMed    


  50. AGUILAR-BRAVO B, Arino S, Blaya D, Pose E, et al
    Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00236-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available



  51. Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries.
    J Hepatol. 2023 Apr 6:S0168-8278(23)00206-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  52. WANG L, Zhu Q, Zhang JD, Zhang Y, et al
    Discovery of a first-in-class orally available HBV cccDNA inhibitor.
    J Hepatol. 2023;78:742-753.
    PubMed     Abstract available


  53. ZHANG F, Xu LD, Zhang Q, Wang A, et al
    Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
    J Hepatol. 2023;78:704-716.
    PubMed     Abstract available


    March 2023
  54. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    PubMed    


  55. CUI A, Li B, Wallace MS, Gonye ALK, et al
    Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
    J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  56. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  57. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    PubMed    


  58. MONTALI I, Berti CC, Morselli M, Acerbi G, et al
    Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
    J Hepatol. 2023 Mar 7:S0168-8278(23)00167-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  59. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
    Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
    J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


    February 2023
  60. ENGELMANN C, Jalan R
    Authors' reply to: G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
    J Hepatol. 2023 Feb 25:S0168-8278(23)00110-1. doi: 10.1016/j.jhep.2023.
    PubMed    


  61. LOHSE AW, Lorgensen MH
    Paediatric Autoimmune Hepatitis: time to change the textbooks?
    J Hepatol. 2023 Feb 23:S0168-8278(23)00105-8. doi: 10.1016/j.jhep.2023.
    PubMed    


  62. RODRIGUEZ C, Marchand S, Sessa A, Cappy P, et al
    Orthohepevirus C hepatitis, an underdiagnosed disease?
    J Hepatol. 2023 Feb 18:S0168-8278(23)00096-X. doi: 10.1016/j.jhep.2023.
    PubMed    


  63. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
    Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
    J Hepatol. 2023;78:293-300.
    PubMed     Abstract available


  64. CARLSON S, Vaz K, Peterson A
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
    J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
    PubMed    


    January 2023
  65. ZOULIM F, Testoni B
    Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
    J Hepatol. 2023 Jan 27:S0168-8278(23)00029-6. doi: 10.1016/j.jhep.2023.
    PubMed    


  66. MAGGIORE G, Bernard O, Mosca A, Ballot E, et al
    Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00025-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  67. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
    PubMed    


  68. LUCIFORA J, Alfaiate D, Pons C, Michelet M, et al
    Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
    J Hepatol. 2023 Jan 23:S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  69. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
    Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  70. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
    3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
    PubMed    


    December 2022
  71. SU J, Brunner L, Oz EA, Sacherl J, et al
    Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    J Hepatol. 2022 Dec 30:S0168-8278(22)03465-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  72. ADRANEDA C, Tan YC, Yeo EJ, Kew GS, et al
    A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    J Hepatol. 2022 Dec 28:S0168-8278(22)03469-9. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  73. LEISKAU C, Tsaka S, Meyer-Ruhnke L, Mutschler FE, et al
    Acute severe non-A-E-hepatitis of unknown origin in children - a 30-year retrospective observational study from north-west Germany.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03464-X. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  74. CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
    Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  75. SHEN Y, Liu Y, Yu K, Shen M, et al
    G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03414-6. doi: 10.1016/j.jhep.2022.
    PubMed    


  76. SNIJDERS RJALM, Gevers TJG, Drenth JPH
    The value of surrogate endpoints and predictive markers in autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03413-4. doi: 10.1016/j.jhep.2022.
    PubMed    


  77. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    PubMed    


  78. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


    November 2022
  79. VAN DER PLUIJM RW, Smits LP, Rebers SP, Schinkel J, et al
    Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir.
    J Hepatol. 2022 Nov 23:S0168-8278(22)03310-4. doi: 10.1016/j.jhep.2022.
    PubMed    


  80. CHOI J
    Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
    J Hepatol. 2022;77:1472-1474.
    PubMed    


  81. YUEN MF, Locarnini S, Lim TH, Strasser SI, et al
    Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    J Hepatol. 2022;77:1287-1298.
    PubMed     Abstract available


    October 2022
  82. ENGEL B, Jaeckel E, Taubert R
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03138.
    PubMed    


  83. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available


  84. AGARWAL K, Lok J, Gane E
    Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy.
    J Hepatol. 2022;77:906-908.
    PubMed    


  85. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    


    September 2022
  86. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    PubMed     Abstract available


  87. GILLICH N, Zhang Z, Binder M, Urban S, et al
    Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03113.
    PubMed     Abstract available


  88. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    PubMed     Abstract available


  89. SUN L, Feng H, Misumi I, Shirasaki T, et al
    Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03120.
    PubMed     Abstract available


  90. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed    


  91. PEETERS M, Schenk J, De Somer T, Roskams T, et al
    Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.
    J Hepatol. 2022 Sep 5. pii: S0168-8278(22)03064.
    PubMed     Abstract available


  92. YI H, Lin Y, Lu B, Mao Y, et al
    The origin of severe hepatitis of unknown aetiology in children: SARS-CoV-2 or adenovirus?
    J Hepatol. 2022 Sep 3. pii: S0168-8278(22)03063.
    PubMed    


  93. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available


  94. CHO Y, Bukong TN, Tornai D, Babuta M, et al
    Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcoholic hepatitis.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03060.
    PubMed     Abstract available


  95. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    PubMed    


    August 2022
  96. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    PubMed     Abstract available


  97. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    PubMed     Abstract available


  98. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    PubMed     Abstract available


  99. SNIJDERS RJALM, Gevers TJG, Heneghan MA, Drenth JPH, et al
    Defining endpoints that guide treatment in autoimmune hepatitis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02991.
    PubMed    


  100. BRUGGEMANN Y, Klohn M, Todt D
    The pivotal role of CD8+ T cells in hepatitis E virus infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02986.
    PubMed    


  101. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    PubMed    


  102. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    PubMed     Abstract available


  103. JORGENSEN MH, Cananzi M, Buescher G, Samyn M, et al
    Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.
    J Hepatol. 2022;77:551-553.
    PubMed    


  104. WONG AM, Ding X, Wong AM, Xu M, et al
    Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/TNFRSF19-mediated immune evasion.
    J Hepatol. 2022;77:410-423.
    PubMed     Abstract available


    July 2022
  105. LI Y, Xiao X, Miao Q, Ma X, et al
    Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.
    J Hepatol. 2022 Jul 20. pii: S0168-8278(22)02945.
    PubMed    


  106. SEMMLER G, Meyer EL, Mandorfer M
    De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.
    PubMed    


  107. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    PubMed    


  108. DANDRI M, Volmari A, Lutgehetmann M
    The hepatitis delta virus and chronic hepatitis D.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)00337.
    PubMed    


  109. PAPATHEODORIDIS GV, Lekakis V, Voulgaris T, Lampertico P, et al
    Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)02935.
    PubMed     Abstract available


  110. BUTI M, Craxi A, Foster GR, Maticic M, et al
    Viral hepatitis Elimination: Towards a hepatitis free world.
    J Hepatol. 2022 Jul 13. pii: S0168-8278(22)02934.
    PubMed    


  111. VAN LEEUWEN LPM, de Jong W, Doornekamp L, van Gorp ECM, et al
    Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment.
    J Hepatol. 2022 Jul 8. pii: S0168-8278(22)02930.
    PubMed     Abstract available


  112. DI DATO F, Di Giorgio A, Mandato C, Maggiore G, et al
    Italian children seem to be spared from the mysterious severe acute hepatitis outbreak: a report by SIGENP Acute Hepatitis Group.
    J Hepatol. 2022 Jul 6. pii: S0168-8278(22)02924.
    PubMed    


  113. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
    PubMed    


  114. AGARWAL K, Lok J, Carey I, Shivkar Y, et al
    A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
    J Hepatol. 2022;77:245-248.
    PubMed     Abstract available


  115. LAI MW, Chang YL, Cheng PJ, Chueh HY, et al
    Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan.
    J Hepatol. 2022;77:63-70.
    PubMed     Abstract available


  116. HUANG D, Wu D, Wang P, Wang Y, et al
    End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    J Hepatol. 2022;77:42-54.
    PubMed     Abstract available


    June 2022
  117. LAMPERTICO P, Roulot D, Wedemeyer H
    BULEVIRTIDE WITH OR WITHOUT PEGIFNalpha FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES.
    J Hepatol. 2022 Jun 22. pii: S0168-8278(22)00373.
    PubMed     Abstract available


  118. HOOGEVEEN RC, Dijkstra S, Bartsch LM, Drescher H, et al
    Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen(+) infection.
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00366.
    PubMed     Abstract available


  119. MEDAS R, Liberal R, Cardoso H, Macedo G, et al
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: a too early endpoint?
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00367.
    PubMed    


  120. YUEN MF, Heo J, Kumada H, Suzuki F, et al
    Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00351.
    PubMed     Abstract available


  121. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    PubMed    


  122. SULKOWSKI MS, Agarwal K, Ma X, Nguyen TT, et al
    Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Jun 10. pii: S0168-8278(22)00348.
    PubMed     Abstract available


  123. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    PubMed    


  124. SZABO G, Thursz M, Shah VH
    Therapeutic advances in alcohol-associated hepatitis.
    J Hepatol. 2022;76:1279-1290.
    PubMed     Abstract available


  125. WONG GLH, Gane E, Lok ASF
    How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    J Hepatol. 2022;76:1249-1262.
    PubMed     Abstract available


    May 2022
  126. ZHANG Z, Ni Y, Lempp FA, Walter L, et al
    Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00338.
    PubMed     Abstract available


  127. KEMMING J, Gundlach S, Panning M, Huzly D, et al
    Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00334.
    PubMed     Abstract available


  128. ZENG G, Huang J
    The recent outbreak of acute severe hepatitis in children of unknown origin.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00332.
    PubMed    


  129. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    PubMed     Abstract available


  130. QIAN Z, Hao X, Xia Y, Yu W, et al
    Rat Hepatitis E virus is a potential zoonotic pathogen to humans.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00327.
    PubMed    


  131. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
    Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
    PubMed     Abstract available


  132. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    PubMed    


  133. MA Z, de Man RA, Kamar N, Pan Q, et al
    Chronic hepatitis E: advancing research and patient care.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00319.
    PubMed     Abstract available


  134. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    PubMed    


  135. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    PubMed    


  136. MUCKE MM, Zeuzem S
    The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
    J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
    PubMed     Abstract available


  137. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    PubMed    


  138. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    PubMed    


  139. LEMON SM
    Hepatitis A: Current view of an ancient disease.
    J Hepatol. 2022 May 2. pii: S0168-8278(21)02091.
    PubMed    


  140. SONNEVELD MJ, Chiu SM, Park JY, Brakenhoff SM, et al
    Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
    J Hepatol. 2022;76:1042-1050.
    PubMed     Abstract available


    April 2022
  141. BAYLIS SA, O'Flaherty N, Burke L, Hogema B, et al
    Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors.
    J Hepatol. 2022 Apr 26. pii: S0168-8278(22)00250.
    PubMed    


  142. TIAN F, Feld JJ, Feng Z, Sander B, et al
    Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
    J Hepatol. 2022 Apr 25. pii: S0168-8278(22)00249.
    PubMed     Abstract available


  143. BOETTLER T, Csernalabics B, Salie H, Luxenburger H, et al
    SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.
    J Hepatol. 2022 Apr 21. pii: S0168-8278(22)00234.
    PubMed     Abstract available


  144. YUEN MF, Agarwal K, Ma X, Nguyen TT, et al
    Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00238.
    PubMed     Abstract available


  145. MAUNG NC, Liew ZHS, Leow WQ, Yeong PSJ, et al
    Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00236.
    PubMed    


  146. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    PubMed     Abstract available


  147. FRASER DA, Wang X, Lund J, Nikolic N, et al
    A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
    J Hepatol. 2022;76:800-811.
    PubMed     Abstract available


    March 2022
  148. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    PubMed    


  149. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    PubMed    


  150. RUTHER DF, Weltzsch JP, Schramm C, Sebode M, et al
    Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care.
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00120.
    PubMed    


  151. GEHRING AJ, Mendez P, Richter K, Ertl H, et al
    Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00127.
    PubMed     Abstract available


    February 2022
  152. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    PubMed     Abstract available


  153. RIVERO-JUAREZ A, Frias M, Perez AB, Pineda JA, et al
    Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00075.
    PubMed     Abstract available


  154. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available


  155. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
    Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
    PubMed     Abstract available


  156. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
    Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
    PubMed     Abstract available


  157. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    PubMed    


    January 2022
  158. BEHRENDT P, Friesland M, Wissmann JE, Kinast V, et al
    Hepatitis E virus is highly resistant to alcohol-based disinfectants.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00019.
    PubMed     Abstract available


  159. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
    Heparanase is upregulated by HCV and favors its replication.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
    PubMed     Abstract available


  160. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    PubMed    


  161. PAPE S, Snijders RJ, Gevers TJ, Chazouilleres O, et al
    Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
    J Hepatol. 2022 Jan 20. pii: S0168-8278(22)00012.
    PubMed     Abstract available


  162. SHEKHTMAN L, Cotler SJ, Ploss A, Dahari H, et al
    Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation.
    J Hepatol. 2022 Jan 4. pii: S0168-8278(21)02307.
    PubMed    


  163. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
    Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
    PubMed     Abstract available


    December 2021
  164. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    PubMed     Abstract available


  165. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
    PubMed     Abstract available


  166. ZHANG M, Zhang Z, Imamura M, Osawa M, et al
    Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models.
    J Hepatol. 2021;75:1335-1345.
    PubMed     Abstract available


    November 2021
  167. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
    PubMed     Abstract available


  168. DE MARTIN E, Duclos-Vallee JC
    Reply to "validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02167.
    PubMed    


  169. TENG Y, Xu Z, Zhao K, Zhong Y, et al
    Novel function of SART1 in HNF4alpha transcriptional regulation contributes to its antiviral role during HBV infection.
    J Hepatol. 2021;75:1072-1082.
    PubMed     Abstract available


    October 2021
  170. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    PubMed     Abstract available


  171. YUAN S, Yang Y, Hu R
    The Unfolding Multiomics Landscapes of HBV (Hepatitis B Virus)-Host Interactions.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02101.
    PubMed    


  172. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
    PubMed     Abstract available


  173. TUN GS, Gleeson D, Dube A, Al-Joudeh A, et al
    Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed.
    J Hepatol. 2021 Oct 4. pii: S0168-8278(21)02093.
    PubMed    


  174. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    PubMed     Abstract available


  175. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    PubMed     Abstract available


  176. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
    Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    J Hepatol. 2021;75:820-828.
    PubMed     Abstract available


  177. MEIER MA, Calabrese D, Suslov A, Terracciano LM, et al
    Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.
    J Hepatol. 2021;75:840-847.
    PubMed     Abstract available


    September 2021
  178. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
    HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
    PubMed     Abstract available


  179. RAHIM MN, Heneghan MA
    Reply to "The Search for Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues".
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02046.
    PubMed    


  180. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available


  181. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    PubMed     Abstract available


  182. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    PubMed     Abstract available


  183. MALLET V, Scarano Pereira JP, Martinino A, Roque-Afonso AM, et al
    The rise of the hepatitis E virus.
    J Hepatol. 2021 Sep 16. pii: S0168-8278(21)00303.
    PubMed    


  184. LACKNER C, Stauber RE, Tiniakos D
    Reply to: Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
    J Hepatol. 2021 Sep 16. pii: S0168-8278(21)02035.
    PubMed    


  185. GAO Y, You M, Fu J, Tian M, et al
    Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    J Hepatol. 2021 Sep 12. pii: S0168-8278(21)02027.
    PubMed     Abstract available


    August 2021
  186. YE Q, Kam LY, Yeo YH, Dang N, et al
    Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.
    J Hepatol. 2021 Aug 30. pii: S0168-8278(21)02014.
    PubMed     Abstract available


  187. CORDES AK, Goudeva L, Lutgehetmann M, Wenzel JJ, et al
    Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02013.
    PubMed     Abstract available


  188. LIN S, Hall A, Kumar R, Quaglia A, et al
    Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)02008.
    PubMed    


  189. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
    PubMed    


  190. DO CARMO RF, de Souza CDF
    Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
    PubMed    


  191. FERNANDO B
    Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: One or Even Several Swallows Do Not Make a Summer.
    J Hepatol. 2021 Aug 9. pii: S0168-8278(21)01965.
    PubMed    


  192. XU H, Locarnini S, Wong D, Hammond R, et al
    Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.
    J Hepatol. 2021 Aug 6. pii: S0168-8278(21)01959.
    PubMed     Abstract available


    July 2021
  193. MISUMI I, Mitchell JE, Lund MM, Cullen JM, et al
    T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
    J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01949.
    PubMed     Abstract available


  194. DELTENRE P, Marot A
    Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
    J Hepatol. 2021 Jul 20. pii: S0168-8278(21)01912.
    PubMed    


  195. BORGIA SM, Shafran SD
    Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
    J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
    PubMed    


  196. KIRCHNER T, Jaeckel E, Falk CS, Eiz-Vesper B, et al
    SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis.
    J Hepatol. 2021 Jul 17. pii: S0168-8278(21)01911.
    PubMed    


  197. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
    Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
    J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
    PubMed     Abstract available


  198. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
    PubMed    


  199. MCSHANE C, Kiat C, Rigby J, Crosbie O, et al
    The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis?
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01896.
    PubMed    


  200. LLEWELLYN HP, Arat S, Gao J, Wen J, et al
    T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01887.
    PubMed     Abstract available


  201. BOLIA R, Srivastava A
    The Search For Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues....
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01890.
    PubMed    


  202. GRANITO A, Muratori P, Muratori L
    Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01884.
    PubMed    


  203. YUAN S, Liao G, Zhang M, Zhu Y, et al
    Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection.
    J Hepatol. 2021;75:74-85.
    PubMed     Abstract available


    June 2021
  204. PAPATHEODORIDI M, Papatheodoridis G
    New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00440.
    PubMed    


  205. CLAYTON-CHUBB D, Schneider D, Freeman E, Kemp W, et al
    Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00427.
    PubMed    


  206. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  207. ARAB JP, Diaz LA, Baeza N, Idalsoaga F, et al
    IDENTIFICATION OF OPTIMAL THERAPEUTIC WINDOW FOR STEROID USE IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS: A WORLDWIDE STUDY.
    J Hepatol. 2021 Jun 21. pii: S0168-8278(21)00439.
    PubMed     Abstract available


  208. TAN CK, Wong YJ, Wang LM, Ang TL, et al
    Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association?
    J Hepatol. 2021 Jun 18. pii: S0168-8278(21)00424.
    PubMed    


  209. BRIL F, Fettig DM
    Response to letter to the editor by Capecchi et al. "Comment to the letter of Bril F et al. "Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?"
    J Hepatol. 2021 Jun 16. pii: S0168-8278(21)00423.
    PubMed    


  210. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  211. LONDONO MC, Gratacos-Gines J, Saez-Penataro J
    Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty?
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00417.
    PubMed    


  212. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
    Anti-epileptic drugs and hepatitis C therapy: real world experience.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
    PubMed    


  213. ROCCO A, Sgamato C, Compare D, Nardone G, et al
    Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty.
    J Hepatol. 2021 Jun 8. pii: S0168-8278(21)00412.
    PubMed    


  214. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    PubMed     Abstract available


  215. LI J, Liang X, You S, Feng T, et al
    Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    J Hepatol. 2021 Jun 3. pii: S0168-8278(21)00399.
    PubMed     Abstract available


  216. DING ZY, Li GX, Chen L, Shu C, et al
    Association of liver abnormalities with in-hospital mortality in patients with COVID-19.
    J Hepatol. 2021;74:1295-1302.
    PubMed     Abstract available


  217. SARRAZIN C
    Treatment failure with DAA therapy: Importance of resistance.
    J Hepatol. 2021;74:1472-1482.
    PubMed     Abstract available


  218. CHEN J, Liu B, Tang X, Zheng X, et al
    Role of core protein mutations in the development of occult HBV infection.
    J Hepatol. 2021;74:1303-1314.
    PubMed     Abstract available


    May 2021
  219. MATHURIN P
    Early liver transplantation for acute alcoholic hepatitis: we can't say no.
    J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
    PubMed     Abstract available


  220. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  221. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
    PubMed    


  222. MARTINEZ MG, Boyd A, Combe E, Testoni B, et al
    Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00348.
    PubMed     Abstract available


  223. DE MARTIN E, Duclos-Vallee JC
    Reply to "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00345.
    PubMed    


  224. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
    Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
    PubMed     Abstract available


  225. RODRIGUES PM, Olaizola P, Banales JM
    Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?
    J Hepatol. 2021 May 10. pii: S0168-8278(21)00183.
    PubMed    


  226. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
    Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
    J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
    PubMed     Abstract available


  227. CRESPO J, Diaz-Gonzalez A, Cabezas J
    HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
    PubMed    


  228. CAPECCHI PL, Lazzerini PE, Brillanti S
    Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?"
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00304.
    PubMed    


  229. ZENG DY, Li JM, Lin S, Dong X, et al
    Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00300.
    PubMed     Abstract available


  230. BREMER W, Blasczyk H, Yin X, Duron ES, et al
    Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00301.
    PubMed     Abstract available


  231. REIG M, Cabibbo G
    Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
    J Hepatol. 2021;74:1225-1233.
    PubMed     Abstract available


  232. HIGASHI-KUWATA N, Hayashi S, Kumamoto H, Ogata-Aoki H, et al
    Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    J Hepatol. 2021;74:1075-1086.
    PubMed     Abstract available


  233. PAPATHEODORIDI M, Hiriart JB, Lupsor-Platon M, Bronte F, et al
    Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
    J Hepatol. 2021;74:1109-1116.
    PubMed     Abstract available


    April 2021
  234. LIBERAL R, Macedo G
    Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.
    J Hepatol. 2021 Apr 29. pii: S0168-8278(21)00297.
    PubMed    


  235. DIETZ J, Sarrazin C
    Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
    PubMed    


  236. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
    Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
    PubMed     Abstract available


  237. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
    DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.
    PubMed    


  238. CANDELS LS, Rahim MN, Shah S, Heneghan MA, et al
    Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates compared to standard weight-based dosing of thiopurine therapy.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00227.
    PubMed     Abstract available


  239. BRIL F, Al Diffalha S, Dean M, Fettig DM, et al
    Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00237.
    PubMed    


  240. WANG W, Lempp FA, Schlund F, Walter L, et al
    Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates.
    J Hepatol. 2021 Apr 9. pii: S0168-8278(21)00229.
    PubMed     Abstract available


  241. GERLICH W
    Hepatitis B virus - an anaerobic organism?
    J Hepatol. 2021 Apr 2. pii: S0168-8278(21)00166.
    PubMed    


  242. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
    Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    J Hepatol. 2021;74:801-810.
    PubMed     Abstract available


    March 2021
  243. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available


  244. CHENG ST, Hu JL, Ren JH, Yu HB, et al
    Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
    J Hepatol. 2021;74:522-534.
    PubMed     Abstract available


    February 2021
  245. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available


  246. IOANNOU GN
    HCC surveillance after SVR in patients with F3/F4 fibrosis.
    J Hepatol. 2021;74:458-465.
    PubMed     Abstract available


    January 2021
  247. SRIDHAR S, Situ J, Cai JP, Yip CC, et al
    Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00013.
    PubMed     Abstract available


    November 2020
  248. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    PubMed     Abstract available


    October 2020
  249. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    PubMed     Abstract available


    March 2020
  250. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
    Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
    PubMed     Abstract available


    February 2020
  251. HAN JW, Sung PS, Hong SH, Lee H, et al
    IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
    PubMed     Abstract available


  252. YEH ML, Huang CF, Huang CI, Holmes JA, et al
    Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
    PubMed     Abstract available


  253. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
    Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
    PubMed     Abstract available


  254. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    PubMed     Abstract available


  255. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    PubMed     Abstract available


    January 2020
  256. TSENG TC, Liu CJ, Chang CT, Su TH, et al
    HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
    J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
    PubMed     Abstract available


    December 2019
  257. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
    High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
    PubMed     Abstract available


  258. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
    Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
    J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
    PubMed     Abstract available


    November 2019
  259. LIU CH, Lee MH, Lin JW, Liu CJ, et al
    Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
    PubMed     Abstract available


  260. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
    B cell immunodominance in primary hepatitis C virus infection.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
    PubMed     Abstract available


  261. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
    Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
    PubMed     Abstract available


  262. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
    PubMed     Abstract available


  263. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
    A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
    PubMed     Abstract available


  264. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    PubMed     Abstract available


    October 2019
  265. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
    Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
    PubMed     Abstract available


  266. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
    Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
    J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
    PubMed     Abstract available


  267. LI Y, Tang L, Guo L, Chen C, et al
    CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
    PubMed     Abstract available


    September 2019
  268. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.